Long-term efficacy and safety of raltegravir in the management of HIV infection

Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun, Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun

Abstract

Raltegravir is an integrase strand-transfer inhibitor approved for the treatment of HIV infection. It was the first medication in a novel class of antiretroviral agents to be approved for use in the United States in 2007. Raltegravir exhibits potent activity against wild-type HIV-1, but resistance development has been noted through three different pathways. It is metabolized primarily through uridine diphosphate glucuronosyltransferase 1A1 and has a single inactive glucuronide metabolite. Raltegravir is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes and exhibits low potential for drug-drug interactions; however, strong uridine diphosphate glucuronosyltransferase 1A1 inhibitors or inducers can alter the pharmacokinetics of raltegravir. It is well tolerated, and the most commonly reported adverse effects include headache, nausea, and diarrhea. Serious adverse effects with raltegravir are rare but include rhabdomyolysis and severe skin and hypersensitivity reactions. It has been approved for use in both treatment-naïve and treatment-experienced patients and is a preferred first-line agent in both United States and European HIV treatment guidelines. Although initial approval was granted on 48-week data, 5-year clinical data have recently been published. This article reviews the data supporting long-term efficacy and safety of raltegravir in the treatment of HIV infection.

Keywords: INSTI; Isentress®; antiretroviral; integrase inhibitor.

References

    1. NME drug and new biologic approvals in 2007 [webpage on the Internet] Silver Spring, MD: US Food and Drug Administration; [Accessed October 31, 2013]. [updated February 10, 2009]. Available from: .
    1. US Food and Drug Administration . FDA approves new combination pill for HIV treatment for some patients [press release] Silver Spring, MD: US Food and Drug Administration; 2012. [Accessed October 31, 2013]. [August 27; updated August 29, 2012]. Available from: .
    1. US Food and Drug Administration . FDA approves new drug to treat HIV infection [press release] Silver Spring, MD: US Food and Drug Administration; 2013. [Accessed October 31, 2013]. [August 12; updated August 13, 2013]. Available from: .
    1. US Food and Drug Administration . Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients [press release] Silver Spring, MD: US Food and Drug Administration; [Accessed October 31, 2013]. [updated July 13, 2009]. Available from: .
    1. US Food and Drug Administration . FDA expands use of HIV drug Isentress to children and adolescents [press release] Silver Spring, MD: US Food and Drug Administration; 2011. [Accessed October 31, 2013]. [December 21]. Available from: .
    1. Lennox JL, DeJesus E, Lazzarin A, STARTMRK investigators Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
    1. Steigbigel AR, Cooper DA, Kumar PN, BENCHMRK Study Teams Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.
    1. Rockstroh JK, DeJesus E, Lennox JL, STARTMRK Investigators Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.
    1. Eron JJ, Cooper DA, Steigbigel RT, BENCHMRK Study Teams Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomized placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587–596.
    1. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51(18):5843–5855.
    1. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) J Virol. 2008;82(2):764–774.
    1. Johns BA, Kawasuji T, Weatherhead JG, et al. Carbamoyl pyridine HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744) J Med Chem. 2013;56(14):5901–5916.
    1. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236–248.
    1. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83(2):293–299.
    1. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–1214.
    1. Wenning L, Anderson M, Petry A, et al. Raltegravir (RAL) dose proportionality and effect of food (abstract H-1046); 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA. September 17–20, 2007.
    1. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67(2):460–464.
    1. Kassahun M, MacIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657–1663.
    1. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623–627.
    1. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47(1):137–140.
    1. Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010;32(6):782–786.
    1. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–2856.
    1. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338–4343.
    1. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52(12):4228–4232.
    1. Barrail-Tran A, Yazdanpanah Y, Fagard C, et al. Lack of Interaction between etravirine and raltegravir plus darunavir/ritonavir when combined in treatment-experienced patients: a substudy of the ANRS 139 TRIO trial (abstract 606); 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 16–19, 2010.
    1. Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol. 2010;69(1):51–57.
    1. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52(9):3253–3258.
    1. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2752–2755.
    1. Cooper DA, Steigbigel RT, Gatell JM, BENCHMRK Study Teams Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355–365.
    1. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489–492.
    1. Rhame F, Matson M, Wood D, et al. Effects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV infected persons (abstract PE4.1/1); 12th Europeans AIDS Conference; Cologne. November 11–14, 2009.
    1. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010;54(12):4999–5003.
    1. Markowitz M, Nguyen BY, Gotuzzo E, Protocol 004 Part II Study Team Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133.
    1. Gotuzzo E, Markowitz M, Ratanasuwan W, Protocol 004 Study Team Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004) J Acquir Immune Defic Syndr. 2012;61(1):73–77.
    1. Raffi F, Rachlis A, Stellbrink HJ, SPRING-2 Study Group Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
    1. Raffi F, Jaeger H, Quiros-Roldan E, SPRING-2 Study Group Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935.
    1. Young B, Vanig T, DeJesus E, SHIELD Study Team 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial. HIV Clin Trials. 2011;12(4):228–233.
    1. Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29(2):256–265.
    1. Gatell JM, Katlama C, Grinsztejn B, Protocol 005 Team Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr. 2010;53(4):456–463.
    1. Grinsztejn B, Nguyen AY, Katlama C, Protocol 005 Team Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261–1269.
    1. Elion R, Molina JM, Ramón Arribas López J, Study 145 Team A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr. 2013;63(4):494–497.
    1. Capetti A, Landonio S, Meraviglia P, et al. 96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicenter Italian experience. PLoS One. 2012;7:e39222.
    1. Fagard C, Colin C, Charpentier C, ANRS 139 TRIO Trial Group Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012;59(5):489–493.
    1. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER) study. AIDS. 2011;25(12):1481–1487.
    1. Gallien S, Braun J, Delaugerre C, EASIER ANRS 138 Study Group Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011;66(9):2099–2106.
    1. Martinez E, Larrousse M, Llibre JM, SPIRAL Study Group Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24(11):1697–1707.
    1. Eron JJ, Young B, Cooper DA, SWITCHMRK 1 and 2 investigators Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicenter, double-blind, randomized controlled trials. Lancet. 2010;375(9712):396–407.
    1. De Castro N, Braun J, Charreau I, EASIER ANRS 138 Study Group Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis. 2009;49(8):1259–1267.
    1. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009;51(4):367–373.
    1. Isentress® (raltegravir) [package insert] Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; 2011.
    1. Madeddu G, Menzaghi B, Ricci E, CISAI Group Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012;26(18):2412–2415.
    1. Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. J Microbiol Immunol Infect. 2013 Apr 20; Epub.
    1. Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS. 2010;21(11):783–785.
    1. Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr. 2013;62(5):525–533.
    1. Monteiro P, Perez I, Pich J, Gatell JM, Martinez E. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013;68(2):404–408.
    1. Isentress (raltegravir potassium) tablet and chewable tablet [webpage on the Internet] Silver Spring, MD: US Food and Drug Administration; 2013. [Accessed September 20, 2013]. [updated November 14, 2013]. Available from: .
    1. Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8(1):e52562.
    1. Saumoy M, Sánchez-Quesada JL, Martínez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis. 2012;225(1):200–207.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; [Accessed October 10, 2013]. [updated February 12, 2013]. Available from: .
    1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.
    1. European AIDS Clinical Society Guidelines. European AIDS Clinical Society; 2013. [Accessed January 29, 2014]. Version 7.0. Available from .
    1. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children; [Accessed October 10, 2013]. [updated November 5, 2012]. Available from: .
    1. Eron JJ, Jr, Rockstroh JK, Reynes J, QDMRK Investigators Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11(12):907–915.
    1. Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6):3101–3106.
    1. Tivicay® (dolutegravir) [package insert] Research Triangle Park, NC: ViiV Healthcare; 2013.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel